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Background: The mode of presentation, clinical, radiologic and laboratory characteristics of patients with acromegaly and the 
outcome following various modalities of treatment are not well documented in South Africa.
Aim: To evaluate treatment outcome and follow-up of patients with acromegaly over a period of 10 years.
Methods: The study is a retrospective record review of patients with acromegaly attending Inkosi Albert Luthuli Central Hospital, 
Durban, 2003–2013.
Results: The study included 27 patients (16 female and 11 male) with a mean age at diagnosis of 44.2 ± 14.0 years. The mean 
growth hormone (GH) at diagnosis was 51.8  ±  32.6  μg/l and mean IGF-1  956.8  ±  432.9  μg/l. In 25 patients (92.5%) pituitary 
macroadenoma was identified; microadenoma was present in 2 (7.4%) patients. Trans-sphenoidal surgery was employed in 26 
(96.3%) as the initial therapy; only 1 patient was treated medically. Adjunctive medical therapy was used in 23 (88.5%) and 
radiotherapy in 6 (22.2%). After a mean follow-up of 4.4 ± 3.4 years, 9 (33.3%) subjects were cured (normal age-matched and 
gender-matched IGF-1 and random GH < 1.0 μg/l). No deaths were recorded and post-procedural hypopituitarism developed in 
22 (84.6%) patients.
Conclusions: Patients with acromegaly in KwaZulu-Natal present with advanced clinical features and large pituitary adenomata. 
The overall cure rate is lower than reported from developed countries.
Keywords: acromegaly, diagnostic criteria, medical and radiotherapy, modes of treatment (surgery)
Introduction
Acromegaly is an acquired endocrine disease due to over-
production of growth hormone (GH), most often from a pituitary 
somatotropinoma and characterised by progressive somatic and 
systemic manifestations.1–3
Excess GH and the subsequent elevation of insulin-like growth 
factor-1 (IGF-1) are the biochemical hallmarks of the disease and 
lead to the characteristic multi-system, often disfiguring, physical 
manifestations as well as the co-morbidities including diabetes 
mellitus (DM), hypertension (HT), arthritis, sleep apnoea and 
cardiovascular disease.4,5
Acromegaly is due to a pituitary adenoma in over 98% of cases, 
either purely GH-secreting (60%) or as part of a pluri-hormonal 
secretory adenoma. In rare cases, acromegaly is caused by 
ectopic secretion of growth-hormone-releasing hormone 
(GHRH) or GH.6 It may present with the following manifestations: 
symptoms and signs of GH hyper-secretion, tumour expansion 
with compression of the adjacent structures (optic chiasm, and 
cavernous sinus) and with the diagnosis of a co-morbid 
condition.7
Treatment strategies for acromegaly aim at reduction in tumour 
size or control of tumour growth, inhibition of GH hyper-
secretion, and normalisation of IGF-1 levels. The three approaches 
to treatment are surgery, medical management and 
radiotherapy.8 The primary treatment is surgical, either trans-
sphenoidal or trans-cranial. Trans-sphenoidal surgery is the 
treatment of choice for intra-sellar microadenomas and non-
invasive macroadenomas. Trans-cranial surgery is reserved for 
patients with invasive or supra-sellar macroadenoma.8
Medical therapy includes three classes of drugs: dopamine 
agonists (DAs), somatostatin receptor ligands (SRL) and GH 
receptor antagonist (GHRA). These are usually adjunctive to 
primary surgical management.8
Radiation treatment (conventional, stereotactic) is rarely used as 
primary therapy and is usually employed following surgical de-
bulking of non-resectable tumours.8
Biochemical criteria for cure of acromegaly have been debated 
over a number of years.9,10 With the improvements in GH assay 
performance, recent guidelines state that patients with random 
serum GH < 2.5 μg/l (measured by standard radio-immunoassay) 
after treatment do not have increased mortality and such 
patients are reported to have a standardised mortality rate (SMR) 
of 1.1 (95% CI 0.9–1.4), compared with an SMR of 1.9 (95% CI 
1.5–2.4) in patients with random GH levels > 2.5 μg/l.8
The achievement of a ‘safe’ GH level and corresponding reduction 
in mortality is influenced by a number of factors, including the 
availability of a skilled and experienced dedicated pituitary 
surgeon and the judicious use of new therapeutic agents.11
In the developed world, acromegaly is able to be cured with a 
combination of surgery, medical therapy and radiotherapy in 
over 60% of subjects. An earlier study of 103 patients in Canada, 
treated with initial surgery, followed by medical therapy or 
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The achievement of a ‘safe’ GH level and corresponding reduction 
in mortality is influenced by a number of factors, including the 
availability of a skilled and experienced dedicated pituitary 
surgeon and the judicious use of new therapeutic agents.11
In the developed world, acromegaly is able to be cured with a 
combination of surgery, medical therapy and radiotherapy in 
over 60% of subjects. An earlier study of 103 patients in Canada, 
treated with initial surgery, followed by medical therapy or 
 
radiotherapy, reported a cure rate of 63%, defined by random GH 
< 2.5 μg/l, or GH nadir in a 75 g oral GTT < 1.0 μg/l and normal 
IGF-1.12 More recently, the large German Acromegaly Register 
study reported on disease control in 1 344 patients, using normal 
or low age- and gender-adjusted IGF-1 as the criterion.13 At the 
last follow up visit, IGF-1 was available for 1 275 subjects and, of 
these, 917 (71.9%) fulfilled the criterion for disease control.13 
Results from the Spanish Acromegaly Register were similar, with 
76% of 698 subjects regarded as controlled, as defined by a 
normal IGF-1 level.14
Whilst acromegaly is well characterised in the developed world, 
there is a paucity of information from Africa and South Africa. 
The available literature from South Africa is limited to a single 
publication. This was a review of the 20-year experience (1974–
1993) of acromegaly at a teaching hospital in Cape Town.11 Of 
the 72 patients in that study, the majority (79%) had a pituitary 
macroadenoma at diagnosis, and after a mean follow-up of 
8.7  years only 43% were deemed to have been cured. After 
follow-up, 23 of 62 (37%) traced patients had died. The most 
frequent cause of death was cerebrovascular disease, although 
in 22% the cause was not defined.11 Only one report is available 
from Africa. In this report, acromegaly patients were addressed 
as part of pituitary tumours in general.9
Reports are available from other developing countries. A 
retrospective study of 15 patients with pituitary macroadenomas 
at a tertiary care hospital in eastern India over a period of four 
years (2007–2011) reported that 10 (66%) patients had trans-
sphenoidal surgery and, of these, cure was achieved in four 
(40%) subjects with no recurrence in the follow-up period.10 The 
remaining five (33%) subjects had no surgery: three (19.8%) of 
the five patients declined surgery and two (13.2%) had co-
morbidities precluding surgery. Five subjects received 
radiotherapy as a primary therapy. All five failed to respond to 
conventional radiotherapy and three (60%) subjects developed 
hypopituitarism.10
The clinical profile and treatment outcome of patients with 
acromegaly in the developed world contrasts with these reports 
from the developing world. There are no studies of patients with 
acromegaly from KwaZulu-Natal to compare with more recent 
reports from the developed world and since Inkosi Albert Luthuli 
Central Hospital (IALCH) is a referral centre for a large catchment 
population, it is important to review the clinical profile and 
treatment outcomes of this disease.
Aim
The aim of the current study was to determine the clinical, 
radiologic and biochemical characteristics before and after 
treatment of all patients with acromegaly attending the 
endocrinology clinic at IALCH between January 2003 and 
January 2013.
Material and methods
Study population and patient selection
The study was a retrospective record review of all patients with 
acromegaly who attended the endocrinology clinic at Inkosi 
Albert Luthuli Central Hospital (IALCH) over a 10-year period: 
2003–2013. IALCH is a public-sector referral hospital in Durban, 
KwaZulu-Natal, providing specialised neurosurgery and 
endocrinology services for the population of KwaZulu-Natal and 
part of the Eastern Cape in South Africa. The population residing 
in these regions exceeds 10 million. Patients were identified at a 
regional level and referred to IALCH for diagnosis and treatment. 
Therefore, the majority of patients with acromegaly using public 
sector health facilities in this drainage area were managed at 
IALCH. The study was approved by the University of KwaZulu-
Natal Biomedical Research Ethics Committee (Ref: BE306/13) and 
the College of Health Sciences Postgraduate Research Committee.
Data collection
For each patient, clinical, laboratory and radiologic data were 
collected from the time of diagnosis and at 3, 6 and 12  months 
post-surgery. Clinical data included demographic details, 
symptoms and signs, co-morbid conditions and medication use. 
Laboratory data included baseline pituitary function, the response 
of GH to glucose suppression in a 75 g oral glucose tolerance test 
(GTT) and measurement of serum IGF-1 levels. The criteria used to 
define cure included a normal age-matched and gender-matched 
IGF-1 and a random GH < 1.0  μg/l.19 Radiologic data included 
tumour size and characteristics as well as information on 
compression of adjacent structures on either computed 
tomography (CT) or magnetic resonance imaging (MRI). In addition, 
details of surgical procedures, including perioperative complications 
and histology findings, were recorded. The requirement for 
postoperative adjunctive medical therapy (including pituitary 
hormone replacement) or radiotherapy was recorded.
Laboratory methods
All the hormonal assays were performed by the Chemical 
Pathology Laboratory at IALCH. GH was measured by 
chemiluminescent immunoassay (Siemens HGH kit on the 
Siemens Immulite 2000 XPi; Siemens, Erlangen, Germany). The 
GH detection limit was 0.05 μg/l with normal reference range of 
0–3 μg/l in males and 0–8 μg/l in females. Intra-assay and inter-
assay coefficients of variation were 3.5% and 6.5% respectively. 
IGF-1 was measured by chemiluminescent immunoassay 
(Siemens IGF1 kit on the Siemens Immulite 2000 XPi). The IGF-1 
detection limit was 20  μg/l and the intra-assay and inter-assay 
coefficients of variation were 3.9% and 8.1% respectively. Other 
hormone measurements included free T3, free T4, thyrotropin 
(TSH), prolactin, random and 8:00 am cortisol, prolactin, follicle-
stimulating (FSH) and luteinising (LH) hormone, gonadal steroids 
and serum and urine osmolality.
Pituitary imaging
Magnetic resonance imaging (MRI) scans were performed in the 
radiology department at Inkosi Albert Luthuli Central Hospital 
with a Siemens symphony 1.5 tesla or Siemens skyra 3 tesla. 
Gadolinium enhancement was utilised routinely unless contra-
indicated.
Statistical methods
Stata® 13.1 software package (StataCorp, College Station, TX, 
USA) was used for statistical analysis. Data were calculated as 
means, standard deviation, medians and inter-quartile ranges 
(IQR) for 4 time points: baseline, 3–6 months post-intervention, 
12  months post-intervention and the most recent review. The 
difference between baseline and each subsequent period was 
calculated and a Wilcoxon sign rank test was used for any change. 




The study group included 27 subjects, 11 (41%) male and 16 
(59%) female, mean age 44.2 ± 14.0 years.
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Clinical features at diagnosis
Table 1 indicates the clinical characteristics at the time of 
presentation. The majority of patients (n = 25, 92.6%) noted a 
change in appearance. The commonest symptom was headache, 
reported by 24 (88.9%) of patients.
Symptoms of hypopituitarism were reported in 10 (37.4%) 
subjects. Three (27.3%) male patients had erectile dysfunction 
and 7 (43.8%) female subjects had menstrual disturbance. The 
predominant physical changes that occurred were increased size 
of hands or feet, and prominent supraorbital ridge. Visual field 
defects were recorded in 17 (62.9%) patients at diagnosis and 
blindness was not reported in any subject.
Comorbidities at presentation
The prevalence of co-morbid medical diagnoses at presentation 
is given in Table 1. The two commonest co-morbid conditions 
were hypertension (n = 14, 51.8%) and diabetes mellitus (n = 7, 
25.9%). Of the subjects with diabetes mellitus, four were treated 
with oral anti-hyperglycaemic therapy, one patient was on 
insulin and two were on both oral therapy and insulin. Other co-
morbidities, diagnosed in fewer subjects, included osteoarthritis, 
goitre and sleep apnoea. In subjects with osteoarthritis, the 
predominant joints affected were knees and hips.
Biochemical tests at baseline
GH and IGF-1 values were available in all patients. At presentation, 
the mean random GH was 57.58 ± 33.54 μg/l, and the mean IGF-1 
was 956.8  ±  432.91  μg/l. Mean IGF-1 was 3.5 times above the 
age-matched and gender-matched reference range. Of the 27 
patients who had a 75  g oral GTT at baseline, 16 (59.2%) had 
normal glucose tolerance, 7 (25.9%) had impaired glucose 
tolerance or impaired fasting glucose and 4 (14.8%) had diabetes. 
None of the patients suppressed GH to < 1.0 μg/l during the GTT. 
The mean GH nadir during the GTT was 34.88  ±  28.43  μg/l. In 
subjects with pituitary macroadenoma, mean GH nadir in the 
GTT was 35.5  ±  29.8  μg/l, as compared with those who had 
pituitary microadenoma in whom the mean GH nadir was 
29.3 ± 14 μg/l (p = ns).
Hyperprolactinaemia was found in 18 (66.6%) patients; the mean 
prolactin level was 16 times above the reference range. Of these 
15 (83%) had a pituitary macroadenoma. Hypopituitarism was 
present in nine (33.3%) patients at baseline. Of these, secondary 
hypothyroidism was found in eight (89%), secondary 
hypogonadism in four (44.4%) and secondary hypoadrenalism in 
one (11%). None had diabetes insipidus at the time of diagnosis 
(Table 2).
Radiology results at baseline
MRI was performed in 23 (85.1%) of the patients and 4 (14.9%) 
had pituitary CT scan. A pituitary adenoma was identified in 27 
(100%) patients; of these, pituitary macroadenoma was found in 
92.5% (n = 25) subjects. Precise measurement of the maximal 
tumour size was reported in 22 (81.4%) patients. Where the 
tumour size was available, the mean (± SD) was 3.0 ± 0.75 cm. Of 
the 25 patients with a pituitary macroadenoma, 18 (72%) 
demonstrated extension beyond the confines of the sella, with 
optic chiasm compression occurring in all these 18 patients; 
extension into the cavernous sinus was reported in 12 of these 
18 patients. Pituitary microadenoma was diagnosed in 2 (7.4%) 
patients. No patients were diagnosed with ectopic GH-secreting 
or GHRH-secreting tumours.
Treatment modalities
Table 3 outlines the mode of therapy. Pituitary surgery was the 
primary therapy in 96.3% (n = 26). All 26 were treated with initial 
trans-sphenoidal surgery and 1 (3.7%) patient was treated with 
medical therapy only. Sixteen (61.5%) patients had a single 
surgical procedure, seven (26.9%) had two surgical procedures, 
two (7.7%) patients underwent three operations and one (3.8%) 
patient required four surgical procedures. Patients with pituitary 
macroadenoma were subjected to a mean of 1.4 ± 0.86 surgical 
procedures as compared with 2.0  ±  0 in those with 
microadenomas (p = 0.1).
Adjunctive medical therapy was administered to 23 (88.5%) of 
the 26 patients who underwent initial surgery. Of these, 6 (26.1%) 
received a somatostatin analogue (SSA) (octreotide) alone, 7 
(30.4%) were treated with a dopamine agonist (DA) (5 with 
bromocriptine and 2 with cabergoline) and 10 (43.5%) received 
both octreotide and a dopamine agonist either sequentially or in 
combination.
Radiotherapy was delivered to six (22.2%) patients. In three 
(50%), conventional fractionated external beam radiotherapy 
was administered, with a mean daily dose of 2.0 ± 0 Gy and mean 
total dose of 49.75 ± 3.68 Gy. In the other three (50%) patients, 
stereotactic radiosurgery was administered as a single treatment 
with a mean dose of 11.5 ± 2.12 Gy. Three of the six (50%) patients 
who had received radiotherapy had hypopituitarism at the most 
recent follow-up. Table 4 indicates the major and minor 
complications of surgery. No record of post-surgical visual loss or 
perioperative mortality was reported. Twelve patients (46.2%) 
had new onset hypopituitarism as a result of surgery.
Table 1: Symptoms, clinical features, pituitary dysfunction and co-
morbidities of acromegaly patients at presentation (n = 27)
Note: *Goitre and diffuse hypopigmented lesions.
Clinical feature n %
Change in appearance 25 92.6
 Increased size of hands or feet 24 88.9
 Prominent supraorbital ridge 24 88.9
 Headache 24 88.9
 Macroglossia 22 81.5
 Interdental separation 21 77.7
 Prognathism 20 74.1
 Visual field defect 17 62.9
 Menstrual disturbance (females) 7 43.8
 Impotence or low libido (males) 3 27.3
 Polyuria 6 22.2
 Polydipsia 6 22.2
 Proximal myopathy 4 14.8
 Galactorrhoea 2 7.4
 Carpal tunnel syndrome 1 3.7
 Other* 6 22.2
Co-morbidities:
 Hypertension 14 51.8
 Diabetes mellitus 7 25.9
 Goitre 4 14.8
 Osteoarthritis 3 11.1
 Sleep apnoea 2 7.4
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 Prominent supraorbital ridge 24 88.9
 Headache 24 88.9
 Macroglossia 22 81.5
 Interdental separation 21 77.7
 Prognathism 20 74.1
 Visual field defect 17 62.9
 Menstrual disturbance (females) 7 43.8
 Impotence or low libido (males) 3 27.3
 Polyuria 6 22.2
 Polydipsia 6 22.2
 Proximal myopathy 4 14.8
 Galactorrhoea 2 7.4
 Carpal tunnel syndrome 1 3.7
 Other* 6 22.2
Co-morbidities:
 Hypertension 14 51.8
 Diabetes mellitus 7 25.9
 Goitre 4 14.8
 Osteoarthritis 3 11.1
 Sleep apnoea 2 7.4
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Surgical complications
Thirteen of the 26 (50%) patients experienced a complication as 
a result of surgery. The most common complications were 
transient diabetes insipidus (10 patients; 38.5%) and 
cerebrospinal fluid leak (9 patients, 34.6%).
Cure and disease control at final follow-up
The final review occurred at a mean follow up period of 
4.4 ± 3.4 years (median follow-up: 3 years; range 0.5–10 years), 
with total cure rate of 33.3% (9 subjects).
IGF-1 levels
All 27 patients had IGF-1 levels done at the most recent visit. 
Mean IGF-1 at final review was 527.76 ± 395.45 μg/l. Nine (33.3%) 
subjects had a normal age-matched and gender-matched IGF-1 
level.
Random GH
All 27 patients had random GH available at the final review. The 
mean GH was 18.60 ± 10.67 μg/l. Twenty (74.1%) subjects had a 
random GH < 5.0  μg/l, 15 (55.5%) < 2.5  μg/l and 9 (33.3%) < 
1.0  μg/l. Seven (25.9%) patients had random GH level above 
5.0 μg/l.
GH nadir in GTT
Only 2 subjects had a GTT at the final follow-up. In these subjects, 
the mean nadir GH was 10.03 ± 3.77 μg/l. Serum IGF-1 in these 
subjects was 1077 μg/l and 181 μg/l, respectively.
MRI scan
At the final review 18 (67%) patients had an MRI scan. In these 
patients, the median tumour reduction compared with baseline 
was –1.2 cm (IQR –1.2 to –0.6), p = 0.012.
Hypopituitarism
Twenty-two of 27 (81.5%) patients required pituitary hormone 
replacement therapy at the final review. Of these, five (22.7%) 
subjects had combined hypothyroidism, hypoadrenalism and 
diabetes insipidus and five (22.7%) had both hypothyroidism 
and hypoadrenalism. The remaining patients required varying 
combinations of replacement therapy.
IGF-1, Random GH levels and pituitary function
Nine (33.3%) of 27 subjects had normal age-matched and 
gender-matched IGF-1 level with random GH level of < 1.0 μg/l at 
the most recent visit. Of the nine subjects with biochemical cure 
of acromegaly, only two subjects had normal pituitary function; 
the remaining patients all required pituitary hormone 
replacement. The only difference between the group who 
achieved cure and those who did not was in baseline skull X-ray 
findings (vault thickening, p = 0.018; sinus enlargement, p = 
0.021). No significant difference was found for baseline GH, IGF1 
or size of tumours between those cured and those with persistent 
active disease at the final review.
Discussion
The current study evaluated the clinical, biochemical and 
radiological features of 27 patients with acromegaly at four 
different periods in order to assess treatment outcome. The 
majority of patients presented with symptoms of the tumour 
mass and pituitary macroadenoma was present in all but two of 
the subjects. Hypopituitarism was present in one-third of 
subjects prior to treatment and this increased to 81.5% after a 
mean follow-up of 4.4 years. Trans-sphenoidal surgery was used 
as the primary treatment modality in 96.3% of the patients, and 
Patient outcome
Six months post-surgery
At the six-month review, the mean random GH and IGF-1 were 
21.7 ± 26.1 μg/l, and 708.88 ± 452.5 μg/l, respectively. Mean GH 
nadir during the GTT was 8.66  ±  4.68  μg/l. Thirteen out of 27 
(48.1%) patients had an MRI scan done at this time point. In these 
patients median tumour reduction, compared with baseline, was 
–0.7  cm (inter-quartile range (IQR) –1.1 to –0.3), p = 0.0088. In 
three patients there was no evidence of tumour.
Twelve months post-surgery
At one-year post surgery, mean random GH was 22.01 ± 25.33 μg/l, 
while the mean random IGF-1 was 794.73 ± 443.28 μg/l. Mean 
GH nadir in GTT was 4.07 ± 2.42 μg/l. Fifteen out of 17 (88.2%) 
patients had an MRI done at this time point. Median tumour 
reduction, compared with baseline, was –1.2  cm (IQR –1.6 to 
–0.2), p = 0.0064. In six patients there was no evidence of tumour 
on MRI.
Table 2: Pituitary function in patients with acromegaly at presentation 
(n = 27)
Diagnosis n %




Diabetes insipidus 0 0
Hyperprolactinaemia 18 66.6 
Table 3: Therapeutic modalities in patients with acromegaly (n = 27)
Note: *Trans-sphenoidal and trans-cranial.
Treatment n %
 Surgery Number of interventions: 26 96.3
 1 16 61.5
 2 7 26.9
 ≥ 3 3 11.5
 Type of surgery:
 Trans-sphenoidal only 22 84.6
 Trans-cranial only 0 0
 Both* 4 15.4
 Other treatment:
 Medical only 1 3.7
 Adjunctive medical 23 88.5
 Radiotherapy only 0 0
 Adjunctive radiotherapy 6 23.1
Table 4: Surgical complications (n = 26)
Complication n %
Cerebrospinal fluid leak 9 34.6
Transient diabetes insipidus 10 38.5
Haemorrhage 1 3.8
Meningitis 1 3.8
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GH < 1.0 μg/l.19 Other reports, such as the study of Mehtap et al. 
from Turkey, have used less stringent criteria for cure (random 
GH < 2.5 μg/l and nadir GH in GTT < 1.0 μg/l).18 The Cape Town 
study defined cure as random GH < 5 mU/l (1.7 μg/l), nadir GH in 
GTT < 2.0 mU/l (0.7 μg/l) and mean GH in GTT < 5 mU/l (1.7 μg/l).11
In the present study, application of the Endocrine Society criteria 
yielded a cure rate of 33.3% (nine subjects fulfilling both IGF-1 and 
GH criteria). However, if compared with the study of Mehtap et al., 
55.5% (15 subjects) in the current study would be regarded as 
cured (based on random GH < 2.5 μg/l). The final GTT results in the 
present study are not able to be used as a means to define cure, in 
view of the small number of subjects who underwent this 
procedure at the final follow-up. The Cape Town study was reported 
in 2001 and older assay methods were used, thereby limiting direct 
comparison; however, using a random GH < 1.7 μg/l (as used in the 
Cape Town study), 44.4% (12 subjects) in the current study would 
be regarded as cured. IGF-1 was not reported in the Cape Town 
study. The Cape Town study reported a cure rate of 28% at the last 
visit.11 In the Mehtap study the cure rate after surgery and 
radiotherapy was 19.3%.18 In the USA and Europe the cure rate was 
57% and 60% respectively.16,20 In the German and Spanish Register 
studies, disease control, defined as a normal IGF-1, was substantially 
higher than in the current study (71.9% and 76% respectively).13,14
The strict definition of cure, however, includes retention of normal 
pituitary function after surgery or radiotherapy. If the criteria of 
normal age-matched and gender-matched IGF-1 together with 
random GH < 1.0  μg/l and normal pituitary function are used; 
only 2 of 27 (7.4%) subjects would be regarded as cured.
Two important limitations of the current study should be 
mentioned. The first is the relatively small number of patients, 
which decreases the strength of statistical analysis. Second is 
that it was a retrospective study as all data were collected based 
on chart review.
Conclusion
Patients with acromegaly in KwaZulu-Natal present with 
advanced clinical features and large pituitary adenomata. The 
overall cure rate is lower than reported from developed countries.
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